Loading...
Gene Editing Royalties And Slow Adoption Will Pressure Results Yet Support Long Term Upside
n/a
n/a
AnalystLowTarget's Fair Value
n/a
1Y
-73.7%7D
-6.3%1Y
-73.7%7D
-6.3%You can edit this narrative until Jan 12 2:05 AM. Then, changes will post as Updates.
Author's Valuation
US$585.7% undervalued intrinsic discount
AnalystLowTarget Fair Value